Miridesap/Dezamizumab | m-entrepreneurship.com

Product Name :
Miridesap/Dezamizumab

Search keywords :
Dezamizumab

drugId :
null

Target Vo:
Serum amyloid P-component

Target Vo Short Name :
SAP

Moa_Name:
Serum amyloid P-component inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Pentraxin Therapeutics

Active Company_Name :

Active Indication_Name:

In Active Indication_Name:
Amyloidosis

Termination Status :
Phase 2 Clinical

China Termination Status :

Highest Status:
Discontinued

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Laminin beta 1 Rabbit mAb manufacturer
GSDMD Antibody Purity & Documentation
Cyclin D2 Antibody (YA789): Cyclin D2 Antibody (YA789) is a non-conjugated and Mouse origined monoclonal antibody about 33 kDa, targeting to Cyclin D2 (6E11). It can be used for WB assays with tag free, in the background of Human.

Author: Betaine hydrochloride

Related Posts